ASCO: Afinitor Quells Herceptin Resistance MedPage Today In the BOLERO-3 trial, everolimus (Afinitor) significantly extended the time before relapse in patients resistant to trastuzumab (Herceptin), reported Ruth O'Regan, MD, of Emory University in Atlanta. There were also fewer deaths among women treated ... |
